{"id":15239,"date":"2025-12-10T15:26:23","date_gmt":"2025-12-10T14:26:23","guid":{"rendered":"https:\/\/www.sciencepharma.com\/blog\/importing-medicinal-products-gmp-requirements-and-customs-clearance-challenges\/"},"modified":"2025-12-16T08:42:54","modified_gmt":"2025-12-16T07:42:54","slug":"importing-medicinal-products-gmp-requirements-and-customs-clearance-challenges","status":"publish","type":"blog","link":"https:\/\/www.sciencepharma.com\/pl\/blog\/importing-medicinal-products-gmp-requirements-and-customs-clearance-challenges\/","title":{"rendered":"Importing Medicinal Products: GMP Requirements and Customs Clearance Challenges"},"content":{"rendered":"

Importing medicinal products into the EU is a highly regulated process that leaves no room for error. From strict <\/span>GMP expectations<\/span><\/strong> to complex <\/span>customs procedures<\/span><\/strong>, each step can affect timelines and product quality. This article explores the main regulatory challenges and highlights practical strategies that help importers avoid delays, ensure compliance, and protect product integrity.<\/span><\/p>\n\n\n

<\/div>\n\n\n\n

Key GMP Requirements for Importing Medicines<\/h2>\n\n\n

Importing medicinal products into the EU<\/span><\/strong> requires strict adherence to <\/span>Good Manufacturing Practice (GMP)<\/span><\/strong> to ensure that products manufactured outside the Union meet standards fully equivalent to those applied within the EU.\u00a0<\/span><\/p>\n\n\n

\n
\n

A central expectation is that every third-country manufacturing site<\/strong> involved in producing, testing, or packaging the product operates under an EU-compliant quality system<\/strong> and holds appropriate evidence of GMP status, such as a valid GMP certificate<\/strong> or inspection record recognised by EU authorities. A key role in the import process <\/span>is carried out<\/span> by the Qualified Person (QP), who must confirm before taking any decision regarding the handling of a batch that the entire supply chain complies with EU GMP requirements. <\/span>This<\/span> includes, among other things, verifying the integrity and completeness of batch documentation, ensuring the suitability of the manufacturing site, and confirming that any deviations, changes, or quality concerns have been <\/span>properly<\/span> investigated and closed. <\/span>The QP reviews all data related to production, transport, and <\/span>quality of<\/span> the batch in accordance with the requirements of <\/span>Annex<\/span> 16 GMP<\/span><\/strong>. <\/span><\/p>\n

Companies importing medicinal products must also hold a valid Manufacturing and Importation Authorisation (MIA)<\/strong>. The scope of this authorisation must reflect the specific dosage forms and activities performed, including storage, sampling, and testing<\/strong>.<\/span><\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

GMP\u2013Customs Interface: How Quality Requirements Affect Clearance Procedures<\/h2>\n\n\n

For many companies, <\/span>customs clearance is the most unpredictable stage of the import process.<\/span><\/strong> Medicinal products are subject to strict scrutiny, and even minor discrepancies in documentation or product information can lead to delays, additional fees, or regulatory interventions.<\/span><\/p>\n\n\n

\n
\n

Quality-related aspects of the product, <\/span><\/strong>such as correct naming, dosage form, batch number, and packaging specifications, can directly affect clearance. Customs authorities routinely verify these details against the documentation submitted by the manufacturer and the importer, checking for consistency across all declarations and supporting records. Any inaccurate or incomplete quality-related information may trigger additional inspections by customs or national regulatory agencies, causing significant delays.<\/span><\/p>\n

Typical issues include:<\/span><\/p>\n